Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy

Mumbai, October 13, 2025 — Bristol Myers Squibb (BMS) has launched its novel cardiovascular drug Mavacamten, under the brand name Kopozgo, in India. This marks the first availability in India of an oral, selective cardiac myosin inhibitor for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). 

What is oHCM & How Kopozgo Works 

• Obstructive hypertrophic cardiomyopathy (oHCM) is a condition in which the heart muscle thickens abnormally, obstructing blood flow and causing symptoms like shortness of breath, chest pain, and fatigue. 

• Traditional therapies (e.g. beta-blockers, calcium channel blockers) generally aim to relieve symptoms, but Kopozgo (Mavacamten) targets the underlying mechanical function of the heart by selectively inhibiting cardiac myosin, which can reduce the obstruction and improve heart function. 

Regulatory Path & Clinical Evidence

• In India, BMS obtained an import license from the CDSCO (Central Drugs Standard Control Organization) in March 2025 to bring in Kopozgo. 

• The approval was supported by results from two Phase 3 clinical trials, EXPLORER-HCM and VALOR-HCM, which showed that Mavacamten had consistent efficacy and an acceptable safety profile in patients with oHCM. 

• Some patients in trials experienced a transient drop in left ventricular ejection fraction (LVEF) (i.e. a temporary decrease in heart pumping efficiency), but these effects reversed once treatment was interrupted. 

Market Context & Potential Impact

• Globally, Mavacamten is marketed under the brand Camzyos, and in 2024, it reported net sales of USD 602 million, reflecting strong uptake in approved markets. 

• BMS acquired the rights to Mavacamten via its 2020 acquisition of MyoKardia. 

• In India, BMS estimates that around 2.8 million people may have oHCM, with 80–90% undiagnosed, presenting a substantial unmet medical need. 

Significance & Challenges

The launch of Kopozgo in India is a landmark as it offers patients and physicians a mechanism-focused therapy for oHCM, rather than just symptomatic relief. However, its success will depend on:

• Safety monitoring and physician education, especially regarding managing LVEF changes

• Access and affordability in the Indian market

• Uptake by cardiologists and acceptance in treatment guidelines

• Real-world data and long-term outcomes